Download THE OPTION OF TRANSPLANTATION

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
THE OPTION OF
TRANSPLANTATION
LILLY BARBA, M.D.
MEDICAL DIRECTOR RENAL
TRANSPLANT PROGRAM
HARBOR-UCLA MEDICAL CENTER
OPTIONS FOR TREATMENT OF
END STAGE RENAL DISEASE
• HEMODIALYSIS
• PERITONEAL DIALYSIS
• TRANSPLANTATION
THE OPTION OF
TRANSPLANTATION
• BEST OPTION TO RESTORE FEELING
OF WELL BEING
• LIBERALIZATION OF FLUID AND
DIETARY RESTRICTION
• ABILITY TO TRAVEL
• INCREASE IN LIFE SPAN AS
COMPARED TO REMAINING ON
DIALYSIS
RISKS OF TRANSPLANTATION
• MAJOR SURGICAL PROCEDURE WITH
POSSIBLE COMPLICATIONS
INCLUDING:
• BLEEDING
• INFECTION
• REJECTION
• ANESTHESIA RISK
• DEATH
OPTION OF
TRANSPLANTATION
• CHOSING THE OPTION OF
TRANSPLANTATION SHOULD BE
TAKEN WITH CAUTION
• IN GENERAL, HOWEVER,
TRANSPLANTATION IS THE BEST
OPTION FOR TREATING PEOPLE
WITH KIDNEY DISEASE
PURSUING THE OPTION OF
TRANSPLANTATION
• PATIENTS MAY BE REFERRED BY
THEIR NEPHROLOGIST WHEN THE
SERUM CREATININE IS 3.5 MG/DL OR
ESTIMATED GFR < 20 CC/MIN
• THE REASON FOR EARLY REFERRAL
IS TO ESTABLISH WAITING TIME OR
READY FOR A PRE EMPTIVE
TRANSPLANT
WAITING TIME
• UNOS (UNITED NETWORK FOR
ORGAN SHARING) IS THE
ORGANIZATION THAT OVERSEES
ALL TRANSPLANT PROGRAMS IN THE
UNITED STATES
• TOLL FREE NUMBER 1-888-894-6361
INFORMATION LINE FOR
TRANSPLANT CANDIDATES,
RECIPIENTS AND FAMILY MEMBERS
UNOS
• UNOS ALSO MAINTAINS A WEB SITE,
TRANSPLANT LIVING, WHICH
CONTAINS INFORMATION FOR
TRANSPLANT CANDIDATES AND
RECIPIENTS AND FAMILY MEMBERS
• ADDRESS:
WWW.TRANSPLANTLIVING.ORG
BENEFITS OF PRE EMPTIVE
TRANSPLANTATION
• NO NEED TO START DIALYSIS: NO
COMORBITIDIES ASSOCIATED WITH
DIALYSIS
• BETTER QUALITY OF LIFE
• HIGHER EMPLOYMENT RATES POST
TRANSPLANT
• NO NEED FOR AV GRAFT OR FISTULA
PLACEMENT
BENEFITS OF PRE EMPTIVE
TRANSPLANTATION
• DO NOT HAVE TO WAIT YEARS FOR A
DECEASED DONOR
• PATIENTS WHO RECEIVE PREEMPTIVE TRANSPLANTS HAVE
BETTER OUTCOMES
• COSTS FOR MAINTAINING A
TRANSPLANT PATIENT ARE LESS
BARRIERS TO PRE EMPTIVE
TRANSPLANTATION
•
2005 USRDS : INCIDENCE OF PRE
EMPTIVE TRANSPLANTATION WAS 2.5%
• NKF CONSENSUS CITED REASONS:
1. EARLY EDUCATION NEEDED
2. TIMELY TRANSPLANT REFERRAL
NEEDED
3. IDENTIFICATION OF POTENTIAL LIVING
DONOR
4. REFERRAL WHEN PATIENT IS REFERRED
FOR AV ACCESS
CANDIDATES FOR
TRANSPLANTATION
THOSE PATIENTS WITH:
• PATIENTS WITH IRREVERSIBLE LOSS
OF RENAL FUNCTION
• THOSE WITH CREATININE > 3.5
MG/DL
• AGE IS A RELATIVE FACTOR IN
DETERMINING CANDIDACY
WHO IS NOT A POTENTIAL
CANDIDATE ?
THOSE PATIENTS WITH:
• ACTIVE INFECTION
• CANCER OR CANCER RECENTLY
TREATED
• UNCORRECTABLE HEART PROBLEMS
• ADVANCED LUNG DISEASE
WHO IS NOT A POTENTIAL
CANDIDATE ?
THOSE PATIENTS WITH:
• ACTIVE STOMACH ULCERS
• CIRRHOSIS OF THE LIVER
• NO ELIGIBILITY FOR INSURANCE OR NO
MEDICAL INSURANCE
• LACK OF A FAMILY/SOCIAL SUPPORT
SYSTEM
• ONGOING KIDNEY DISEASE: VASCULITIS
WHO IS NOT A POTENTIAL
CANDIDATE ?
THOSE PATIENTS WITH:
• MORBID OBESITY
• SEVERE PSYCHIATRIC PROBLEMS
NOT WELL CONTROLLED
• CONTINUED ALCOHOL, TOBACCO
OR ILLICIT DRUG ABUSE
• AGE GREATER THAN 70 WITHOUT
THE POTENTIAL FOR A LIVING
DONOR
THOSE PATIENTS WITH PCKD
•
OVERALL, PATIENTS WITH PCKD DO
WELL
• PRE TRANSPLANT CLEARANCE MAY
INCLUDE:
1. CT SCAN OF THE ABDOMEN
2. CT SCAN OF THE BRAIN
3. ECHOCARDIOGRAM
4. SURGICAL REMOVAL OF NATIVE
KIDNEYS
THE TRANSPLANT SURGICAL
PROCEDURE
WHAT YOU SHOULD EXPECT
FOLLOWING TRANSPLANT
SURGERY
• SURGERY IS 3 – 5 HOURS UNDER GENERAL
ANESTHESIA
• HOSPITAL STAY 5 – 7 DAYS
• AFTER SURGERY:
–
–
–
–
–
–
FOLEY CATHETER
JACKSON PRATT DRAINAGE BULB (JP)
CENTRAL VENOUS PRESSURE LINE (CVP)
STAPLES HOLDING WOUND TOGETHER
POD # 1 : BEDREST
POD # 2: START EATING
POD # 3: WALKING AS TOLERATED
IMMUNOSUPPRESSIVE
MEDICATIONS
• CNI (TACROLIMUS OR
CYCLOSPORINE)
• STEROID (PREDNISONE)
• ANTI-METABOLITE (CELLCEPT OR
AZATHIOPRINE)
MEDICATIONS CAN HAVE SIDE
EFFECTS: COMMON SIDE
EFFECTS
• TACROLIMUS/CYCLOSPORINE :
TREMORS, HIGH BLOOD PRESSURE,
HAIR GROWTH WITH
CYCLOSPORINE, POSSIBLE DIABETES
• PREDNISONE: GASTRITIS, WEIGHT
GAIN SECONDARY TO INCREASE
APPETITE, DIFFICULT TO CONTROL
DIABETES, ACNE, EASY BRUISING,
INCREASE SENSITIVITY TO THE SUN
MEDICATIONS CAN HAVE SIDE
EFFECTS: COMMON SIDE
EFFECTS
• CELLCEPT: GAS, DIARRHEA, LOW
WHITE BLOOD CELL COUNT
TRANSPLANTATION OPTIONS
•
•
•
PRE-EMPTIVE TRANSPLANTATION
LIVING DONOR TRANSPLANTATION
DECEASED DONOR
TRANSPLANTATION:
1. STANDARD CRITERIA
2. EXTENDED CRITERIA
3. DONOR AFTER CARDIAC DEATH
LIVING DONORS
• ANY PERSON WHO IS HEALTHY CAN
BE EVALUATED FOR A TRANSPLANT
• CANNOT HAVE DIABETES,
HYPERTENSION, KIDNEY DISEASE
OR ACTIVE DRUG USE
• EACH TRANSPLANT PROGRAM SETS
CRITERIA FOR DONOR
LIVING DONORS DO WELL
• SURGERY IS USUALLY DONE
LAPARASCOPICALLY
• HOSPITAL STAY IS 3 DAYS MAXIMUM
• PAIN CONTROLLED WITH
NARCOTICS
• RESUMPTION OF DAILY ACTIVITES
IN 4 TO 8 WEEKS
LIVING DONORS DO WELL
• RESUMPTION OF NORMAL DAILY
ACTIVITIES WITH 4 TO 8 WEEKS
LIVING DONORS DO WELL
• RISKS LOW: MORTALITY 0.03 %, SURGICAL
RISKS ABOUT 3 %
• LONG TERM RISKS: HAVE TO BE
EVALUATED IN CONTEXT OF PRE
EXISITING PROBLEMS, DEVELOPMENT OF
MEDICAL PROBLEMS AFTER DONATION
AND GENERAL POPULATION RISKS OF
DEVELOPING KIDNEY DISEASE WHICH IS
APPROXIMATELY 2 % FOR CAUCASIANS
AND 7.5 % FOR AFRICAN AMERICANS
LIVING RELATED DONATION
IN PKD FAMILIES
• OWING TO THE DIFFICULTIES
ENCOUNTERED IN EXCLUDING PKD
IN RELATED POTENTIAL DONORS,
PATIENTS WITH PKD RECEIVE
FEWER LIVING RELATED KIDNEY
TRANSPLANTS
LIVING RELATED DONATION
IN PKD FAMILIES
• ULTRASOUND IS INSUFFICIENTLY
INSENSITIVE TO EXCLUDE DISEASE
BEFORE THE AGE OF 30 YEARS
• GENETIC TESTING CAN BE USED
THROUGH ANALYSIS OF LINKED
FLANKING POLYMORPHIC GENETIC
MARKERS OR THE USE OF DIRECT
MUTATION ANALYSIS
DECEASED DONORS
• DIFFERENCE IN ALLOGRAFT
SURVIVAL
• DECEASED DONOR HALF-LIFE 7 TO 12
YEARS
• LIVING DONOR HALF-LIFE IS 20
YEARS
• RISK OF REJECTION MAY BE HIGHER
ESPECIALLY IS DONOR IS NOT
RELATED TO RECIPIENT
WAITING TIME FOR A
DECEASED DONOR
• BLOOD GROUPS ARE O, A, AB, B
• AVERAGE WAITING TIME FOR AN O
KIDNEY IS THE GREATER LA AREA IS
7 TO 10 YEARS
• B PATIENTS WAIT GREATER THAN 5
YEARS
DISCUSSION WITH
TRANSPLANT CENTER
• WHICH IS THE BEST OPTION FOR
ME?
• EVALUATION OF POTENTIAL
DONORS
• COMPLETION OF WORK-UP IN A
TIMELY BASIS
• HEAR ALL THE OPTIONS
CONCLUDING REMARKS
• TRANSPLANTATION IS THE BEST
OPTION FOR PATIENTS WITH
KIDNEY DISEASE
• COMPLICATIONS ARE POSSIBLE
• LIVING DONATION IS ENCOURAGED
ESPECIALLY TO EXPEDITE
TRANSPLANTATION, FOR LONG
TERM SUCCESS